Nebenwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.8 · PDF-Seite 26–27
HOS-114873 · Präparat HOS-094169
26 Paediatric population In an open-label, dose-finding study of tipranavir plus ritonavir (Trial 1182.14), 28 children who were 12 years of age or above received Aptivus capsules. In general, adverse reactions were similar to those seen in adults, with the exception of vomiting, rash and pyrexia, which were reported more frequently in children than in adults. The most frequently reported moderate or severe adverse reactions in the 48 week analyses are noted below.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage b3373b6e7b50e67275e2449a3ca39e02aa9d9a2ba93fdbc0bf237f6e38832029 · Zeichen 9204–9674 im Abschnitt